Joshua Marcus

Executive Director, Chief Intellectual Property Counsel Insmed Incorporated

Leading IP strategy for a rapidly growing biopharmaceutical company with 850+ issued patents and pending patent applications, Joshua Marcus sits at the intersection of scientific innovation, AI and IP protection. Insmed generated $606M in product revenue in 2025 and is expanding a diverse pipeline spanning respiratory, immunology, gene therapy and other rare diseases, making the strategic protection of emerging innovation increasingly critical. With Insmed already using AI across drug discovery, development and commercialisation, Josh brings a timely perspective on how IP leaders can capture the value of AI-enabled innovation while ensuring the underlying inventions, data and know-how remain protected.

Day 1

8:50 AM PANEL DISCUSSION: OWN YOUR WINS - BALANCE AI GENERATED INNOVATION WITH IP PROTECTION

AI is now embedded in how organisations invent, draft, search and market but much of what GenAI touches may be difficult to protect or enforce if you don't set clear guardrails. Explore how to are use AI in patent and brand work while still "owning the win".

Identify where GenAI can safely support invention, drafting, search and brand work; and where you need strict human-only or "internal AI only" rules to preserve IP and enforceability.
Take away practical guardrails: what data must never go into external tools, how to record human vs AI contribution, and contract language for agencies/partners so ownership and liability are clear.
See how peers are rebalancing patents, trade secrets and contractual rights in line with emerging USPTO/EPO guidance and AI case law, so today's AI-enabled innovations remain defensible assets in 3–5 years.

Check out the incredible speaker line-up to see who will be joining Joshua.

Download The Latest Agenda

In Partnership With:

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: +44 (0) 207 368 9484
Fax: 44 (0) 207 368 9301
Email: exchangeinfo@iqpc.com